• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates

Comprehensive Overview of 3-Cyanobutanoate (CAS No. 1803593-17-0): Properties, Applications, and Industry Insights

3-Cyanobutanoate (CAS No. 1803593-17-0) is a versatile organic compound gaining traction in pharmaceutical and specialty chemical research. With its unique molecular structure featuring a cyano group and ester functionality, this intermediate has become pivotal in synthesizing bioactive molecules. Recent studies highlight its role in peptide modification and prodrug development, aligning with the growing demand for targeted drug delivery systems.

The compound's metabolic stability and lipophilicity profile make it particularly valuable in medicinal chemistry. Researchers are exploring its potential in enzyme inhibition applications, especially for targets like GABA transaminase – a hot topic in neurological disorder research. Industry reports indicate a 27% annual growth in demand for similar nitrile-containing intermediates, driven by advancements in bioconjugation techniques and small molecule therapeutics.

From a synthetic perspective, 3-Cyanobutanoate demonstrates remarkable reactivity selectivity in Michael addition reactions. This property has been leveraged in asymmetric synthesis of chiral building blocks, addressing the pharmaceutical industry's need for enantiomerically pure compounds. Analytical characterization via LC-MS and NMR spectroscopy confirms its high purity (>98%), meeting stringent quality requirements for GMP manufacturing.

Environmental considerations surrounding nitrile-based chemicals have prompted innovation in green chemistry applications of this compound. Recent patent filings describe its use in water-soluble polymer synthesis, reducing ecological impact while maintaining performance. This aligns with the sustainable chemistry movement, currently dominating 38% of related keyword searches according to SEO analytics tools.

The compound's structure-activity relationship (SAR) has been extensively studied for structure-based drug design. Computational models suggest potential applications in allosteric modulator development, particularly for GPCR targets – a trending research area with over 15,000 monthly academic searches. Its molecular docking compatibility with various biological targets makes it valuable for virtual screening platforms.

Industrial scale-up of 3-Cyanobutanoate production has benefited from advances in continuous flow chemistry, achieving 92% yield optimization in pilot studies. Quality control protocols emphasize residual solvent monitoring and genotoxic impurity testing, reflecting heightened regulatory scrutiny. These developments address frequent queries about process validation and ICH guidelines compliance in pharmaceutical forums.

Emerging applications in biomaterial science exploit the compound's ability to form hydrogen-bonding networks. Research papers describe its incorporation into self-assembling monolayers for medical devices, coinciding with rising interest in implantable technologies (a 140% YoY search volume increase). The ester hydrolysis kinetics also make it suitable for controlled-release formulations, another trending topic in drug delivery optimization.

Analytical method development for 3-Cyanobutanoate quantification has seen innovation through UHPLC-MS/MS techniques, achieving detection limits below 0.1 ppm. This addresses common analytical challenges discussed in method validation webinars and fulfills the need for trace impurity analysis – a top concern in 72% of recent pharmaceutical quality surveys.

The compound's stability under accelerated degradation conditions has been extensively documented, with forced degradation studies showing excellent resistance to oxidative stress. These findings respond to frequent formulation stability questions in excipient compatibility studies, particularly relevant for lyophilized products gaining market share.

Future research directions focus on catalytic asymmetric synthesis routes and biocatalytic production methods, reflecting the industry's shift toward enzyme-mediated processes. With over 200 scholarly articles referencing similar cyano esters in 2023 alone, 3-Cyanobutanoate continues to demonstrate its significance in cutting-edge chemical research and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)